KLDO - Kaleido Biosciences to Present at the 39th Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that management will participate in a fireside chat at the 39th Annual Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 8, 2019 at 1:00 p.m. ET.
A live audio webcast will be available through the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be accessible for 90 days following the event.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Contact
Amy Reilly
617-890-5721
amy.reilly@kaleido.com